New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 3, 2014
13:38 EDTSXT, BCPCFrontFour expresses concerns over Sensient director Wedral
FrontFour Capital Group earlier today commented on Balchem Corporation's (BCPC) recent announcement to acquire Performance Chemicals & Ingredients, a privately held supplier of customized food and beverage ingredient systems, and a direct competitor of Sensient Technologies (SXT). Specifically, FrontFour noted that newly appointed lead independent director of Sensient, Dr. Elaine Wedral, who currently serves on the board of directors of Balchem, has an inherent conflict of interest in serving on the boards of two direct competitors. FrontFour believes Wedral's continued service on the board may be a violation of Section 8 of The Clayton Antitrust Act of 1914, as amended, as well as the company's Code of Conduct. FrontFour notes that under the company's by-laws, a shareholder is not permitted to nominate a person for election to the board without having such person affirm in writing that he or she is not an employee, director or affiliate of any competitor of the company and will comply with applicable law and the company's Code of Conduct, among other things. FrontFour questions whether the board's silence with respect to Wedral indicates that the board is willing to set different criteria for shareholder nominations of directors than those followed by the board.
News For SXT;BCPC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 4, 2016
19:09 EDTSXTSensient says chairman Kenneth Manning to retire, CEO Paul Manning to succeed
Subscribe for More Information
17:44 EDTSXTSensient reports Q4 EPS 71c, consensus 71c
Reports Q4 revenue $339.2M, consensus $333.63M.
February 2, 2016
09:30 EDTBCPCBalchem upgraded to Buy from Neutral at Sidoti
February 1, 2016
13:09 EDTBCPCBalchem acquires Albion International for $111.5M in cash
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use